BioNTech (NASDAQ:BNTX) has agreed to acquire its German rival CureVac (NASDAQ:CVAC) in an all-stock transaction worth nearly $1.25B, the companies announced Thursday.
In the premarket trading, shares of CureVac (NASDAQ:CVAC) jumped ~26% in reaction to the announcement, while
